 This study suggests that infliximababda may be effective in treating severe COVID-19 cases. It appears to reduce inflammation and improve survival rates. Further research is needed to confirm these findings. This article was authored by Hillel Hachem, Amandeep Godara, Courtney Schroeder, and others.